Molecular Psychiatry (2002) 7, 110–112  2002 Nature Publishing Group All rights reserved 1359-4184/02 $15.00 www.nature.com/mp ORIGINAL RESEARCH ARTICLE Codon 311 (Cys → Ser) polymorphism of -2 is associated with apolipoprotein E4 allele in both Alzheimer’s and vascular dementias Z Janka1, A Juha´sz1,A´ Rimano´czy1, K Boda2,JMa´rki-Zay3 and J Ka´lma´n1

1Department of Psychiatry; 2Medical Informatics, Albert Szent-Gyo¨rgyi Center for Medical and Pharmaceutical Sciences, Faculty of Medicine, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary; 3Central Laboratory, Be´ke´s County Hospital, PO Box 46, H-5701, Gyula, Hungary

Keywords: paraoxonase; apolipoprotein E; genetic mark- Table 1 Frequency distribution of PON2 and apoE geno- ers; Alzheimer’s disease; vascular dementia; DNA polymor- types and alleles in the control, Alzheimer’s and vascular phism dementia populations The gene of an esterase , called paraoxonase (PON, EC.3.1.8.1.) is a member of a multigene family that Control Alzheimer’s Vascular comprises three related PON1, PON2, and PON3 dementia dementia with structural homology clustering on the 7.1,2 The PON1 activity and the polymorphism of the PON2 genotype PON1 and PON2 genes have been found to be associa- CC 4 (8%) 2 (4%) 3 (6%) ted with risk of cardiovascular diseases such as hyper- CS 20 (39%) 23 (43%) 19 (34%) cholesterolaemia, non-insulin-dependent diabetes, coron- SS 27 (53%) 28 (53%) 33 (60%) ary heart disease (CHD) and myocardial infaction.3–8 The PON2 allele importance of cardiovascular risk factors in the patho- C (cys) 28 (27%) 27 (25%) 25 (23%) mechanism of Alzheimer’s disease (AD) and vascular S (ser) 74 (73%) 79 (75%) 85 (77%) dementia (VD)9–13 prompted us to examine the genetic ApoE genotype effect of PON2 gene codon 311 (Cys→Ser; PON2*S) 22 – – – polymorphism and the relationship between the PON2*S 2 3 6 (12%) 3 (6%) 6 (11%) allele and the other dementia risk factor, the apoE poly- 2 4 – – 1 (2%) morphism in these dementias. The PON2*C and PON2*S 3 3 38 (74%) 32 (60%) 32 (58%) allele frequencies were similar in both AD (25% and 3 4 6 (12%) 15 (28%) 14 (25%) 75%) and VD groups (23% and 77%), respectively, com- 4 4 1 (2%) 3 (6%) 2 (4%) pared with the controls (27% and 73%). The ratio of the ApoE allele PON2*S carriers was significantly higher among the 2 6 (6%) 3 (3%) 7 (6%) apoE4 allele carrier AD (27%) and VD (25%) groups than 3 88 (86%) 82 (77%) 84 (76%) in the control (12%). Our results indicate that the PON2*S 4 8 (8%) 21 (20%) 19 (17%) and apoE4 alleles have interactive effect on the develop- ment of the two most common forms of dementias AD and VD, and further support the hypothesis that cardio- vascular factors contribute to the development of AD. quencies is different in the normal Hungarian popu- Molecular Psychiatry (2002) 7, 110–112. DOI: 10.1038/ lation from that in the Asian Indian, the only available sj/mp/4000916 examined group from the literature.14 The Hungarians have less CC (8%) and more SS (53%) genotypes than Until now there were no data available about the PON2 the Asian Indians have, 17.5% and 40.2% respectively. codon 311 polymorphism in the normal Hungarian In the Hungarian sample the PON*S allele was more population (Table 1). On the other hand significant frequent (73%) than in the Asian Indian group exam- inter-racial variability in the allelic distribution of ined (61%).14 other PON-like genes (PON1 and PON2) and risks asso- The contains three PON-like genes ciated with CHD were reported.14–16 Since the Hung- close to each other, but the function of these arian population is considered to be genetically and is still not clear.2 Recently PON1 has emerged as an linguistically different from the other European ethnic independent risk factor for cardiovascular disease. groups and genetic differences have been reported in Despite the lack of its natural substrate there is growing other lipid metabolism related genes such as the apoE evidence suggesting that as well as catalysing the polymorphism,17,18 it is also important to examine the hydrolysis of nerve toxic organophosphates, when inter-ethnic differences of other genetic risk factors PON1 is associated with high density lipoprotein such as the PON2 mutation. Our results indicate that (HDL), it may protect against LDL oxidation and pre- the distribution of the PON2 genotype and allele fre- vent formation by hydrolysing lipid Paraoxonase-2 gene polymorphism in Alzheimer’s and vascular dementias Z Janka et al 111 peroxides, leukotriene-like compounds and therefore Table 2 PON2 allele frequencies among the apoE4 allele car- inhibiting the oxidation of HDL and low density lipo- riers and non-carriers (LDL).19,20 Furthermore, reduced PON1 activity has been found in patients with the risk of cardiovascu- PON2 Controls Alzheimer’s Vascular lar diseases such as hypercholesterolaemia, non-insu- allele dementia dementia lin-dependent diabetes, coronary heart disease and myocardial infarction.3–5 On the other hand, not only C E2 or E3 26 (25%) 20 (19%) 18 (16%) PON1 activity, but also the polymorphism of the PON1 E4 2 (2%) 7 (7%) 7 (6%) a and PON2 genes has been found to be associated with S E2 or E3 62 (61%) 50 (47%) 58 (53%) b c the same cardiovascular risk factors and diseases.6–8 E4 12 (12%) 29 (27%) 27 (25%) Among the two common genomic variations of the a ␹2 = = Ͻ PON1 gene, the codon 148 (Ala→Gly) mutation was probe 8.523; df 4; P 0.014. b ␹2 probe = 8.18; df = 1; P Ͻ 0.006. reported to be associated with non-insulin-dependent c ␹2 probe = 5.166; df = 1; P Ͻ 0.027. diabetes21 and might worsen glycaemia and lipidaemia in diabetic patients. The codon 192 mutation of the same gene was associated with the risk of coronary no interactive effect was examined with the apoE4 heart disease and had a synergistic effect with the allele. Our results indicate that atheroclerosis-related codon 311 (Cys→Ser) polymorphism of another gene, genetic risk factors might have importance in the the PON2 from the PON gene family.14 It is pertinent to development of the two most frequent dementing dis- mention here that alterations of the serum PON activity orders, AD and VD. Therefore, besides the reported have been described in AD recently,22 but the PON1 lipid metabolism-related risk factors such as the apoE gene polymorphism was not associated with either the polymorphism and the apo A-IV codon 360 mutation,24 severity of the atherosclerosis or the AD-like neuro- the PON2 codon 311 (Cys→Ser) mutation might have pathology in a different AD population.23 Here we had an interactive effect together with the apoE4 allele on similar results with the polymorphism of the PON2 the development of dementia. gene and found that the frequencies of the PON2*S allele were 75% and 77% in the AD and VD groups, Methods respectively, and no significant differences were found compared with controls (73%) (Table 1). Our results Case ascertainment and diagnosis indicate that it is unlikely that the codon 311 One hundred and fifty-nine Caucasian probands par- (Cys→Ser) polymorphism of the PON2 gene alone has ticipated in our study. The 51 normal control persons an impact on the development of AD and VD. Further- (mean age ± SD, 71.8 ± 7 years; male/female 24/27; more another cardiovascular disease and AD-related Mini-Mental State Exam (MMSE) score ± SD, 28 ± 1.3 risk factor, the apoE polymorphism, was also deter- points) were spouses of the AD and VD probands and mined in the present study. It was found that the apoE none of them had verified symptoms of dementia. The 3/4 genotype was more frequent, 28% and 25% in the 53 AD (mean age ± SD, 66.3 ± 10 years; male/female AD and VD groups, than in the control group (12%) 17/36; MMSE score ± SD, 19 ± 2.2 points) and 55 VD (Table 1). The E4 allele was over-represented in both (mean age ± SD, 72.9 ± 10.8 years; male/female 23/32; dementia groups (20% AD and 17% VD) compared MMSE score ± SD, 22 ± 3.5 points) patients were selec- with the controls (8%). One limitation of our study was ted from the outpatients of the local Memory Clinic. that the dementia cases were only clinically diagnosed The clinical diagnosis of late onset sporadic AD was as AD and VD, and no autopsy data are available. based on the DSM-III-R and NINCDS-ADRDA criteria. Therefore we can not exclude the possibility that our The AD probands were considered sporadic type, VD group may include a substantial portion of mixed because none of them had a family history of dementia. AD and VD cases. This potential diagnostic inaccuracy The probable VD cases were diagnosed according to might explain the similarity of the E4 allele frequencies the criteria of ICD-10 and NINDS-AIREN for research reported here in the AD and VD groups. studies. All patients underwent CT, MRI and SPECT To investigate whether the PON2*S and apoE4 studies in order to exclude any other neurological dis- alleles are interactive regarding the dementia risk, the order. None of the probands had diabetes mellitus PON2 allele frequencies were calculated among the according to their blood sugar examination. Informed apoE4 allele carriers and non-carriers (Table 2). consent was obtained from each participant. The study Although the frequency of the PON2*S allele was com- was approved by the local Human Biomedical parable in both dementia cases and controls, it was sig- Research Ethics Committee. nificantly (P Ͻ 0.014) higher among the apoE4 allele carrier AD and VD cases (27% and 25% respectively) Genetic analyses than in the corresponding controls (12%). The PON2*C Total genomic DNA was extracted from white blood allele was also more frequent among the AD (7%) and cells using the method of Miller et al.25 For the PON2 VD (6%) cases than in the control group (2%) but the genotyping the DNA was amplified and the PCR reac- difference was not significant (P Ͻ 0.106). Similar tion products were digested as proposed by Sanghera results with increased PON2*S allele frequency have et al.14 The forward primer 5Ј-ACA TGC ATG TAC been reported in association with CHD by others,14 but GGT GGT CTT ATA-3Ј and the reverse primer 5Ј-AGC

Molecular Psychiatry Paraoxonase-2 gene polymorphism in Alzheimer’s and vascular dementias Z Janka et al 112 AAT TCA TAG ATT AAT TGT TA-3Ј were used to 11 Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure amplify the target region. The PCR-amplified product and dementia in elderly people: the Kungsholmen project. Br Med J 1996; 312:805–808. was detected by DdeI restriction enzyme followed by 12 Ka´lma´nJ,Juha´sz A, Csa´sza´r A, Kanka A, Maglo´czky E, Bencsik K site fractionation on 8% polyacrylamide gel and vis- et al. Apolipoprotein E allele frequencies in patients with late onset ualization of bands with ethidium bromide. The apoE sporadic Alzheimer’s dementia in Hungary. Acta Neurol Scand genotyping was performed as described earlier.12 1997; 95:56–59. 13 Ka´lma´nJ,Juha´sz A, Csa´sza´r A, Kanka A, Rimano´czy A´ , Janka Z et al. Increased apolipoprotein frequency is associated with vascular Statistical analysis dementia in the Hungarian population. Acta Neurol Scand 1998; Age and MMSE scores were normally distributed and 98: 166–168. compared by t-test. Alleles and genotypes were coun- 14 Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphism ted and their distribution between the groups was com- in two paraoxonase genes (PON1 and PON2) are associated with × the risk of coronary heart disease. Am J Hum Genet 1998; 62: pared by 2 2 tables using Fisher’s exact test. Pearson 36–44. ␹2 test was used if less than five variables were counted 15 Antakainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen within one subgroup. All significance tests were two- E, Jauhiainen M et al. The Gln-Arg 192 polymorphism of the tailed. The data were analyzed using SPSS for Win- human paraoxonase gene (HUMPONA) is not associated with the risk of the coronary artery disease in Finns. J Clin Invest 1996; 98: dows (version 8.0) 883–885. 16 Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F et al. The Gln-Arg 192 polymorphism of human Acknowledgements paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998; 18: 1611– The authors wish to thank all the probands who par- 1616. ticipated in the study. This work has been supported 17 Harding RM, Sokal RR. Classification of the European language by a grant from the Health Scientific Board ETT families by genetic distance. Proc Natl Acad Sci USA 1988; 85: 01817/2000, Hungary. 9370–9372. 18 Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csa´sza´rAet al. The apolipoprotein E polymorphism: a comparison References of allele frequencies and effects in nine populations. Am J Hum Genet 1991; 49:338–349. 1 Sorenson RC, Primo-Parmo SL, Camper SA, La Du BN. The genetic 19 Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, mapping and gene structure of mouse paraoxonase/arylesterase. La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation Genomics 1995; 30: 431–438. and preserves its functions. A possible peroxidative role for 2 Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human paraoxonase. J Clin Invest 1998; 101: 1581–1590. serum paraoxonase/arylesterase gene (PON1) is one member of a 20 Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman multigene family. Genomics 1996; 382: 498–507. AM et al. Protective effect of high density lipoprotein associated 3 McElween J, Mackness MI, Colley CM, Perad T, Warner S, Walker paraoxonase. J Clin Invest 1995; 96: 2882–2891. CH. Distribution of paraoxonase hydrolytic activity in the serum of 21 Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B patients after myocardial infarction. Clin Chem 1986; 32:671–673. et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and 4 Mackness MI, Harty D, Bhatnagar D, Winocur PH, Arrol S, Ishola paraoxonase activity and concentration in non-insulin dependent M et al. Serum paraoxonase activity in familial hypercholesterol- diabetes mellitus. Atherosclerosis 1998; 139:341–349. aemia and insulin-dependent diabetes mellitus. Atherosclerosis 22 Ka´lma´n J, Kudchodkar BJ, Murray K, McConathy WJ, Juha´sz A, 1991; 86:193–199. Janka Z et al. Evaluation of serum-lipid related cardiovascular risk 5 Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. factors in Alzheimer’s disease. Dementia Geriatr Cogn Dis 1999; Serum paraoxonase activity, concentration, and phenotype distri- 10: 488–493. bution in diabetes mellitus and its relationship to serum lipids and 23 Sodeyama N, Yamada M, Itoh Y, Suematsu N, Matsushita M, lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 1812–1818. Otomo E. No association of paraoxonase gene polymorphism with 6 Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G atherosclerosis or Alzheimer’s disease. Neurology 1999; 53: et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart 1146–1148. disease in type 2 diabetes. Lancet 1995; 346:869–872. 24 Csa´sza´rA,Ka´lma´n J, Szalai Cs, Janka Z, Romics L. Association of 7 Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P et the apolipoprotein A-IV codon 360 mutation in patients with Alzh- al. Paraoxonase polymorphism Met-Leu54 is associated with modi- eimer’s disease. Neurosci Lett 1997; 230:1–4. fied serum concentrations of enzyme. A possible link between the 25 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure paraoxonase gene and increased risk of cardiovascular disease in for extracting DNA from human nucleated cells. Nucl Acid Res diabetes. J Clin Invest 1997; 99:62–66. 1988; 16: 1215–1218. 8 Rice GI, Ossei-Gerning N, Stickland MH, Grant PJ. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart dis- Correspondence: J Ka´lma´n, Department of Psychiatry, Albert Szent- ease. Coronary Artery Disease 1997; 8:677–682. Gyo¨rgyi Center for Medical and Pharmaceutical Sciences, Faculty of 9 De la Torre JC. Critical threshold cerebral hypoperfusion causes Medicine, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Alzheimer’s disease? Acta Neuropathologica 1999; 98:1–8. Hungary. E-mail: jkalmanȰnepsy.szote.u-szeged.hu 10 Sparks DL. Intraneuronal ␤-amyloid immunoreactivity in the CNS. Received 28 November 2000; revised 26 February 2001; accepted 28 Neurobiol Aging 1995; 17:291–299. February 2001

Molecular Psychiatry